MA40781A - Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale - Google Patents

Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale

Info

Publication number
MA40781A
MA40781A MA040781A MA40781A MA40781A MA 40781 A MA40781 A MA 40781A MA 040781 A MA040781 A MA 040781A MA 40781 A MA40781 A MA 40781A MA 40781 A MA40781 A MA 40781A
Authority
MA
Morocco
Prior art keywords
isotretinoin
pharmaceutical composition
oral use
low dosage
dosage
Prior art date
Application number
MA040781A
Other languages
English (en)
Inventor
Ravi Kochhar
Harish Kumar Madan
Sumit Madan
Rathinasabapathy Venkateshwaran
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55629490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40781(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MA40781A publication Critical patent/MA40781A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA040781A 2014-10-01 2015-05-28 Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale MA40781A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2827DE2014 2014-10-01

Publications (1)

Publication Number Publication Date
MA40781A true MA40781A (fr) 2017-08-08

Family

ID=55629490

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040781A MA40781A (fr) 2014-10-01 2015-05-28 Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale

Country Status (10)

Country Link
US (1) US20160128962A1 (fr)
EP (1) EP3200877A4 (fr)
JP (1) JP6707532B2 (fr)
AU (1) AU2015326489A1 (fr)
BR (1) BR112017006779A2 (fr)
CA (2) CA2963206C (fr)
MA (1) MA40781A (fr)
MX (2) MX377579B (fr)
RU (1) RU2707753C2 (fr)
WO (1) WO2016051288A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40447A (fr) * 2014-07-31 2016-02-04 Sun Pharmaceutical Ind Ltd Composition pharmaceutique orale d'isotrétinoïne
WO2017203365A1 (fr) 2016-05-26 2017-11-30 Dr. Reddy's Laboratiories Ltd. Compositions pharmaceutiques pour le traitement de l'acné
WO2018073751A1 (fr) * 2016-10-17 2018-04-26 Sun Pharmaceutical Industries Limited Procédé de traitement de l'acné
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
JP2024178478A (ja) * 2021-11-04 2024-12-25 興和株式会社 医薬品
JP2024178477A (ja) * 2021-11-04 2024-12-25 興和株式会社 カプセル剤
MA69876A1 (fr) 2022-07-01 2025-11-28 Acrotech Biopharma Inc. Compositions pharmaceutiques comprenant de l'isotrétinoïne ainsi que leurs procédés de préparation et leurs utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001227A1 (es) * 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
FR2807662A1 (fr) * 2000-04-12 2001-10-19 Cll Pharma Procede pour stabiliser la granulometrie d'un principe actif verulent disperse dans un liquide et ses applications
US7435427B2 (en) * 2000-09-22 2008-10-14 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
WO2003047497A1 (fr) * 2001-12-06 2003-06-12 Ranbaxy Laboratories Limited Compositions d'isotretinoine nanoparticulaire
WO2012053013A2 (fr) * 2010-10-21 2012-04-26 Cadila Healthcare Limited Compositions pharmaceutiques d'agents anti-acné
US20120321579A1 (en) * 2011-01-24 2012-12-20 Anterios, Inc. Surfactant compositions
US9078925B2 (en) * 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
WO2016189481A1 (fr) * 2015-05-25 2016-12-01 Sun Pharmaceutical Industries Limited Composition pharmaceutique orale à dosage quotidien unique

Also Published As

Publication number Publication date
JP6707532B2 (ja) 2020-06-10
WO2016051288A1 (fr) 2016-04-07
CA3207801A1 (fr) 2016-04-07
RU2017114924A3 (fr) 2019-01-16
MX2017004312A (es) 2017-07-07
MX2020009444A (es) 2020-10-08
EP3200877A1 (fr) 2017-08-09
AU2015326489A1 (en) 2017-04-27
BR112017006779A2 (pt) 2018-01-09
CA2963206C (fr) 2023-09-26
JP2017530149A (ja) 2017-10-12
RU2017114924A (ru) 2018-11-02
US20160128962A1 (en) 2016-05-12
RU2707753C2 (ru) 2019-11-29
EP3200877A4 (fr) 2018-05-23
CA2963206A1 (fr) 2016-04-07
MX377579B (es) 2025-03-10

Similar Documents

Publication Publication Date Title
EP3256138A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3565550A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3621621A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3294212A4 (fr) Administration de médicament à partir d'hydrogels
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
MA54716A (fr) Réduction de la viscosité de formulations pharmaceutiques
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
EP3541385A4 (fr) Formulations pharmaceutiques
HUE062579T2 (hu) Baktériumokat tartalmazó orális gyógyszerészeti formuláció
MA42303A (fr) Formulations pharmaceutiques
MA43705A (fr) Formulation pharmaceutique
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
FR3027521B1 (fr) Compositions pour administration par voie orale
MA47516A (fr) Composition pharmaceutique
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
IL269884B1 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
EP3318259A4 (fr) Composition pharmaceutique stable pour administration par voie orale
EP2964195A4 (fr) Composition semi-solide pharmaceutique d'isotrétinoïne
EP3459369A4 (fr) Composition pharmaceutique utilisant la souchelactobacillus
MA49837A (fr) Compositions pharmaceutiques
EP3582759A4 (fr) Composition pharmaceutique bioéquivalente de bromhydrate de vortioxétine
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
EP3377111A4 (fr) Promédicaments d'amine de composés pharmaceutiques